Actualités de - During a press conference in Geneva this morning, Martin Velasco, Pascal Mock MD and Prof. Patrick Aebischer, President of the EPFL (Ecole Polytechnique Fédérale de Lausanne), presented a solution which opens promising new prospects in terms of assisted reproductive technology. - A major advantage of the leading-edge technique developed by the Swiss biotech company Anecova SA is that it constitutes a return to a solution which is closer to the natural process. Thus, fertilization and embryonic development take place in vivo (within a capsule in the future mother's uterus) rather than in vitro (in a test tube). - Anecova has now announced proven results which were better than anticipated. This is a major challenge, as sterility now affects one in ten couples, or more than 80 million people throughout the world. Geneva